Autologous whole-cell tumor vaccination {#Sec1}
=======================================

Autologous tumor cells are an obvious source of tumor-associated antigens (TAA) for vaccination purposes, since, by definition, all relevant candidate TAA should be contained within them. Vaccination with irradiated tumor cells has been studied in various animal models as early as the 1970s. Pioneered by Hanna et al. irradiated hepatocellular carcinoma cells were used as a vaccine in a guinea pig model and, admixed with bacillus calmette-guérin (BCG) as an immune adjuvant, were found to generate protective immunity against subsequent challenge with syngeneic non-irradiated tumor cells \[[@CR17], [@CR18]\]. Of note, these early guinea pig studies revealed the importance of vaccinating with live tumor cells, suggesting either a) the direct involvement of the tumor cells themselves in antigen presentation or b) the importance of prolonged expression and release of TAA to allow for sufficient uptake by and activation of immune effector cells. Before general acceptance of the concept of cross-priming, the former was actually regarded as the more obvious explanation.

Colorectal cancer {#Sec2}
-----------------

Building on this pre-clinical work, Hoover et al. conducted a clinical trial in which patients with stage II/III colorectal cancer were vaccinated with irradiated autologous tumor cells and BCG, randomized versus surgery alone \[[@CR24]\]. Subgroup analysis revealed significant overall and disease-free survival for vaccinated patients. In addition, delayed type hypersensitivity (DTH) reactions to autologous tumor cells suggested the presence of tumor-specific immunity. Side effects were minimal and consisted mostly of ulceration of the vaccination sites caused by the BCG adjuvant.These promising results prompted the initiation of a large phase III study of stage II/III colon cancer patients conducted under the auspices of the eastern cooperative oncology group (ECOG) \[[@CR20]\]. This study differed from the Hoover study in that, due to the large number and wide geographic distribution of participating sites, each site manufactured its own vaccines. In an intent-to-treat analysis of all randomized patients, no significant differences were observed between the two treatment arms in time to recurrence or overall survival. In the ECOG study, 12% of all vaccines failed to meet quality control specifications (in terms of cell number and/or viability), and 15% of the vaccinated patients failed to develop DTH reactions to tumor cells alone. Importantly, DTH reactivity to autologous tumor cells did correlate with survival \[[@CR20]\]. It was therefore assumed that poor quality of a part of the vaccines and variability introduced by manufacture at different sites were at the root of the disappointing clinical results of this study. Indeed, survival analysis of patients who were treated with vaccines that met standardization criteria and who actually developed anti-tumor immunity (as determined by DTH reactivity) did show a significant improvement in overall survival. These findings underlined the necessity of standardized vaccine manufacture to make any meaningful comparisons in outcome between vaccinees: a particular challenge in an autologous set-up.

A third phase III study was conducted at our laboratory in the VUmc, involving 254 patients with stage II/III colon cancer \[[@CR62]\]. This pivotal study differed from the previous ECOG study in that a centralized manufacturing laboratory (i.e.the VUmc) supported the 12 participating hospitals, resulting in 98% quality approved vaccines and a rate of 97% measurable DTH reactivity upon vaccination (i.e. \>5 mm). In an intent-to-treat analysis, autologous tumor cell + BCG vaccination significantly reduced the rate of disease recurrence by 44% in patients with stage II/III colon cancer, but the overall survival was not significantly affected. A larger impact was apparent in stage II disease, where a 61% risk reduction for recurrences and a trend toward improved overall survival was observed. These data clearly indicate that the centralized and routine manufacture of quality-controlled vaccines is of the utmost importance for the performance of a successful immunization trial.

A meta-analysis was performed which included the above described three randomized trials for colorectal cancer \[[@CR19]\]. In the intent-to-treat meta-analysis of all 723 patients who received either a three- or a four-vaccine regimen, recurrence-free survival was significantly improved by autologous whole-cell tumor vaccination. However, no significant overall survival benefit could be demonstrated.

While these studies showed promise, more recent FDA prerequisites have complicated the production and quality assurance of these autologous whole-cell tumor based vaccines for colon cancer. Particularly sterility requirements are posing a considerable challenge for an autologous whole-cell vaccine derived from an organ as rife with commensal bacteria as the colon. These restrictions were enforced despite the fact that empirically, in over 200 vaccinated patients, these colon-associated bacteria (whether admixed with BCG or not) were never found to cause any untoward side effects. These regulatory hurdles, combined with financial restraints, have led to the premature termination of a Phase III trial carried out in our clinics at the VUmc, studying the effect of whole-cell colon tumor vaccination combined with 5-FU chemotherapy versus chemotherapy only, in patients with Stage III colon cancer.

Melanoma {#Sec3}
--------

Fostering the autologous whole-cell vaccine + BCG approach, a clinical study was performed at the VUmc with 81 stage III/IV metastatic melanoma patients \[[@CR1]\]. Forty-nine of these patients had no sign of residual disease after metastasectomy, although the chances of tumor recurrence were considered high. After metastasectomy whole-cell tumor vaccines were produced of the resected tumor tissue. One month after surgery the first of three weekly administered irradiated vaccines was administered intradermally in one of the lower extremities. In patients with evidence of disease during the vaccination period (*n* = 38) no clinical responses occurred and no survival benefit was apparent when compared to historical controls. In patients without evidence of disease (stage III, *n* = 35 and stage IV, *n* = 14), the 5-year overall survival rate approximated 45%, which was superior to historical controls (at 35% and 20% for Stage III and IV, respectively) \[[@CR1]\]. In addition, DTH reactivity to tumor cells was found to correspond positively with overall survival \[[@CR1]\]. Finally, this study revealed that the size of DTH-reactions waned after consecutive non-BCG-containing vaccinations, even in patients that after a follow-up period of over five years proved to be free of melanoma. This observation strongly suggests that booster vaccinations can only be effective when co-administered with an immunostimulating adjuvant.

Berd et al. also developed and clinically tested an autologous melanoma cell vaccine, haptenated with dinitrophenyl (DNP), and also combined it with BCG as adjuvant \[[@CR3]\]. After an inclusion period of more than 10 years they reported a 5-year relapse free survival of 33% and an overall survival of 44% for a non-randomized trial with 214 enrolled stage III melanoma patients. These survival rates were considered superior to historical control survival data. Of note, they also observed an association of overall survival and disease free survival with the induction of DTH reactivity to unmodified (non-haptenated) autologous melanoma cells \[[@CR3]\].

Renal cell cancer {#Sec4}
-----------------

In a large multi-center Phase III trial carried out in Germany, 558 patients with a renal cell tumor were pre-operatively randomized to receive either six monthly intradermal autologous tumor vaccines or no adjuvant therapy \[[@CR30]\]. Tumor cells were pre-treated with IFN-γ to upregulate MHC levels and underwent six freeze-thaw cycles prior to administration. No further immune adjuvants were added to the vaccines. 5-year progression-free survival was 77.4% in the vaccinated patients as compared to 67.8% in the untreated patients. Although promising, these results might have been improved upon through the inclusion of a strong immune adjuvant in the vaccine formulation. Although BCG proved its worth as immune adjuvant, the resulting ulcers at vaccination sites eventually disqualified it as the adjuvant of choice for cancer vaccination. The identification of hypomethylated CpG sequences derived from bacterial DNA as the immune-activating component of BCG \[[@CR31], [@CR32]\] led to the design of a Phase II trial at the VUmc in which patients with advanced Renal Cell Cancer were vaccinated with an autologous whole-tumor cell vaccine admixed with a combination of CpG (type-B, PF-3512676), IFNα, and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as adjuvant. The first three induction vaccinations were given weekly followed by subcutaneous administration of IFN-α (6 MIU) and PF-3512676 (8 mg bi-weekly). After 3 months tumor evaluation was performed and in case of a remission or stable disease patients continued with 3 monthly vaccinations and PF-3512676/IFN-α. This vaccination schedule resulted in a 20% clinical response rate in association with a strong anti-tumor DTH skin reactivity \[[@CR59]\]. This study clearly showed the equivalence of this adjuvant combination to BCG in terms of immune activation, without the ulcer formation usually associated with BCG.

GVAX: from autologous towards allogeneic tumor vaccination {#Sec5}
==========================================================

GM-CSF is a 23-kDa glycoprotein that was initially developed for its activity as a hematopoietic growth factor \[[@CR52]\]. Subsequent studies revealed its interesting immunological features \[[@CR8], [@CR10]\]. GM-CSF can overcome tumor-induced immune suppression and promotes the recruitment and maturation of specialized antigen-presenting cells (APC). GM-CSF-mediated activation of APC results in upregulation of MHC class II, co-stimulatory molecules and cytokine production. It increases antibody responses and cellular immunity after immunization.These combined features have made GM-CSF the most commonly used cytokine to boost anti-tumor immunity \[[@CR8], [@CR10], [@CR29]\]. In a murine melanoma model Dranoff et al. demonstrated the potency of prophylactic GM-CSF-transduced autologous tumor cell vaccines in prevention of tumor outgrowth \[[@CR9]\]. Based on this preclinical work, autologous melanoma tumor cells, transduced with GM-CSF (GVAX), were applied clinically and shown to induce tumor-specific immunity and durable anti-tumor responses in a number of trials \[[@CR22]\].

Mouse studies clearly demonstrated the efficacy of GVAX to depend on the cross-presentation of vaccine-derived TAA to specific cytotoxic T lymphocytes (CTL) in vivo \[[@CR22]\]. This process of cross-priming is facilitated by the activation of professional APC, the so-called Dendritic Cells (DC), by GM-CSF. This finding led to the realization that allogeneic cells would also present a viable source of TAA, which would be taken up by DC and then presented in the context of appropriate MHC alleles to autologous CTL. Advantages to the use of allogeneic cells are obvious: (1) through the use of antigenically well-defined cell lines one has access to a sustained and virtually limitless source of TAA, (2) the use of cell lines allows for the highly standardized and large-scale production of allogeneic vaccines, (3) the use of a single batch of allo-vaccines for all vacinees, independent of HLA haplotype, eliminates variability in the quality and composition of the vaccines and facilitates reliable comparative analysis of clinical outcome, and (4) eliminating the need for the continuous production of tailor-made individual vaccines simplifies the logistics and reduces the laboriousness of the vaccine production and delivery process and increases its cost-effectiveness.

Taking these considerations into account, autologous GVAX approaches have been replaced by allogeneic GVAX formulations. Jaffee et al. tested an allogeneic pancreatic cancer vaccine as an adjuvant therapy after pancreaticoduodenectomy in a phase I dose-escalating study and found no noteworthy toxicity, while some patients showed increased DTH-skin reactivity to autologous tumor cells, indicative of the generation of relevant anti-tumor immunity \[[@CR28]\].

Prostate cancer {#Sec6}
---------------

Michael et al. showed the feasibility of allogeneic prostate cancer vaccination: vaccines consisting of three prostate tumor cell lines were i.d. injected monthly over the course of a year in patients with hormone refractory prostate cancer \[[@CR35]\]. The first two vaccines were admixed with BCG. Decreases in PSA velocity were observed in 11/26 patients with an overall median time to disease progression of 58 weeks as compared to 28 weeks in historical controls. Interestingly, while non-responders showed a mixed Th1/Th2 response upon restimulation with a vaccine lysate, responders showed a Th1 cytokine release profile.

Prostate GVAX consists of two prostate cancer cell lines, LNCaP and PC-3, each of which has been genetically modified to secrete GM-CSF. Following manufacture of the transduced cell lines, the cells are lethally irradiated to prevent further cell division upon vaccination. In phase I/II studies the vaccine was generally well tolerated and demonstrated anti-tumor activity \[[@CR11], [@CR44], [@CR46]\]. The largest of these was a multi-center phase I/II trial in 55 patients with HRPC \[[@CR46]\]. Thirty-four patients with metastases showed an overall median survival of 26 months, which compares favorably with median survival times observed in phase II taxane chemotherapy trials in similar patients with HRPC \[[@CR37], [@CR46], [@CR42]\]. Induction of sero-immune reactivity against the prostate cancer cells was demonstrated by Western blot. A smaller phase I/II trial was carried out in hormone therapy-naive patients with a prostate-specific antigen (PSA) relapse following radical prostatectomy and absence of radiological metastases \[[@CR44]\]. Treatments were administered weekly via intradermal injections of Prostate GVAX for 8 weeks. Twenty-one patients were enrolled and treated. Toxicities included local injection-site reactions, pruritus, and flu-like symptoms. At 20 weeks post first treatment, 16 of 21 (76%) patients showed a statistically significant decrease in PSA velocity compared with pre-vaccination (*P* \< 0.001) \[[@CR44]\]. Clinical efficacy of Prostate GVAX is currently tested in metastatic prostate cancer patients in two phase III randomized studies (VITAL-1 and -2). In the first study GVAX is compared to Docetaxel plus prednisone and in the second study GVAX in combination with docetaxel is compared to docetaxel alone. The results are eagerly awaited.

While GVAX monotherapy has shown moderate clinical efficacy, this may be improved upon through interference with checkpoints at the T-cell level that under normal circumstances serve to reinforce tolerance but that in tumor-conditioned environments may suppress appropriate anti-tumor immune responses. The CTL Antigen-4 (CTLA-4) receptor represents such a crucial checkpoint \[[@CR12]\]. It is expressed on activated T-cells and binds to CD86 and CD80 on DC with higher avidity than its competitor ligand CD28. In contrast to CD28, CTLA-4 relays inhibitory signals to the T cell and blocks activating signals originating from CD28-CD86/CD80 interactions. CTLA-4 blockade breaks through inhibitory feedback loops in tumor-specific T-cells and may thus lead to expansion of effector CTL with possibly a higher functional avidity \[[@CR12]\]. In mouse tumor models, the combination of GM-CSF-secreting vaccines and CTLA-4-blocking antibodies has resulted in improved anti-tumor immunity and protection from tumor outgrowth. Both in the B16 melanoma model and in TRAMP, a transgenic murine model of spontaneously arising prostate cancer, the administration of either anti-CTLA-4 mAbs or vaccination with GM-CSF transfected tumor cells had minimal to no effect on tumor rejection. In marked contrast, treatment with the combination of anti-CTLA-4 and GM-CSF-transduced tumor cells at the time of tumor inoculation significantly reduced tumor incidence \[[@CR26], [@CR60], [@CR61]\]. This anti-tumor effect was shown to be CTL-mediated and T helper cell (Th) independent, and indicates that CTLA-4 blockade can lower the threshold of required activating signals such that Th-mediated activation of DC is no longer needed for the provision of a "license to kill" to CTL \[[@CR61]\]. While Phase I/II clinical trials studying monotherapy with either Prostate GVAX or anti-CTLA-4, have shown feasibility of treatment with either modality without severe side-effects and with modest signs of possible clinical efficacy \[[@CR11], [@CR44], [@CR46], [@CR47]\], the aforementioned pre-clinical studies clearly demonstrated a potentially increased efficacy of anti-CTLA-4 as part of a combinatorial approach with Prostate GVAX. This led to the initiation of a Phase I clinical study in the VUmc, in which chemo-naive patients with metastatic hormone refractory prostate cancer (HRPC) receive the allogeneic prostate GVAX immunotherapy combined with infusions of ipilimumab/anti-CTLA-4. This trial represents the first clinical application of the GVAX/anti-CTLA4 combination. In the dose escalation part of this trial, the combination of GVAX immunotherapy with high doses of ipilimumab (3 or 5 mg/kg) has led to promising clinical results with some clear PSA responses \[[@CR16]\]. The trial has now entered its expansion phase with an accrual of 16 patients to be treated at the MTD of ipilimumab, determined in the escalation phase to be 3 mg/kg. To demonstrate immune effects of this treatment and possibly correlate these with clinical efficacy, we are extensively monitoring dendritic and T-cell functions. The results may aid in the rational design of clinical follow-up studies. Final analysis will be performed after concluding the expansion phase of this Phase I trial.

DC-based tumor vaccination: the case for an allogeneic source of DC {#Sec7}
===================================================================

DC are uniquely able to initiate primary immune responses. Myeloid DC differentiate from CD34^+^ hematopoietic progenitor cells (HPC) and can develop into two recognized subsets, Langerhans Cells (LC, expressing the characteristic C-type Lectin Langerin and containing Birbeck Granules \[BG\]), which are mostly found in stratified epithelia, and Interstitial DC (IDC, expressing the C-type Lectin DC-SIGN), which are mostly located in connective tissues. Because of their critical role in orchestrating the immune response, DC are now widely applied in vaccines for the treatment of cancer \[[@CR4]\]. So far, the vast majority of clinical vaccination trials utilized Monocyte-derived DC (MoDC, i.e. IDC equivalents), while only few trials have made use of DC derived from CD34^+^ precursors (CD34-DC \[[@CR4]\]). Nevertheless, it has been suggested that CD34-DC are more effective anti-tumor T-cell inducers than MoDC, both in vitro and in clinical DC vaccination studies \[[@CR2], [@CR14]\]. This favorable effect might be due to "contaminating" LC in the CD34-DC preparations \[[@CR38]\]. DC may be pulsed with TAA-derived epitopes in various ways: through loading with proteins or peptides, through incubation with tumor lysates or apoptotic bodies, through fusion with tumor cells, through transfection with DNA or RNA, or through viral transduction. In various trials anti-tumor immunity as well as clinical efficacy of DC-based tumor vaccination have been reported, particularly for melanoma \[[@CR33]\]. So far, wide-scale implementation has proven to be unattainable for any of the tested DC-based vaccines. A case in point was recently provided by sipuleucel-T (APC8015), which consists of a DC-like fraction enriched from autologous peripheral blood, pulsed with a prostate TAA/GM-CSF fusion protein. Despite a favorable survival benefit in a randomized Phase III trial of 225 patients with metastatic prostate cancer \[[@CR45]\] and an initial positive verdict on safety and clinical efficacy from an FDA advisory committee, it was denied FDA approval, just falling short of becoming the first FDA-approved cell-based vaccine product \[[@CR15]\]. The FDA decision letter called for additional proof of clinical efficacy from an ongoing randomized Phase III trial (a new interim analysis of which is expected mid-2008) and more detailed information on the manufacturing process \[[@CR15], [@CR63]\]. Certainly, multiple hurdles are to be taken in the development of such autologous DC precursor-based immunotherapies as they are: (a) hard to standardize, resulting in highly variable results, complicating the evaluation of clinical trials, and often resulting in negative clinical trial outcomes, (b) laborious and time consuming, and therefore c) very expensive \[[@CR33]\]. These drawbacks have thusfar precluded wide-scale application of autologous DC-based vaccines. In addition, although conflicting reports exist on this matter, there have been indications for an inferior T-cell-stimulatory phenotype of DC derived from advanced cancer patients \[[@CR21], [@CR36]\], which would also argue against the use of autologous DC.

An alternative approach which has recently been explored is the use of allogeneic DC as vaccine vehicles. A major advantage of the use of alloDC is the feasibility of preparing large clinical-grade batches that may be used for all patients, thus providing a more standardized DC vaccine in terms of phenotype and maturation status. As with allogeneic tumor cell-based vaccines, bypassing the need for individually prepared vaccines represents a considerable logistic advantage. Although seemingly counter-intuitive, from a theoretical point of view alloDC-based vaccines might even induce a stronger vaccine-specific immune response than autoDC \[[@CR13]\]. Since an estimated 1--10% of the circulating T cell repertoire is directed against allo-antigens, alloDC may be expected to trigger a broadly reactive T-cell response with two possible advantages: (1) activation of tumor-reactive T-cells through fortuitous cross-reactivity and (perhaps more likely and more importantly:) (2) allo-antigens on the DC may provide T helper (Th) epitopes aiding in the optimal activation of Cytotoxic T Lymphocytes (CTL) against the tumor-related vaccine payload \[[@CR13]\].

Several mouse studies have compared the use of alloDC versus syngeneic DC as fusion partners for syngeneic tumor cells, creating a DC-tumor hybrid vaccine, and consistently shown equal or even superior protection against tumor outgrowth with alloDC \[[@CR43], [@CR48], [@CR51], [@CR58]\]. The anti-tumor responses were mostly shown to be CTL-mediated. Mechanistically, observed advantages of the use of alloDC hybrids seemed to be related to skewing towards a type-1 cytokine response as compared to the use of syngeneic DC \[[@CR43], [@CR48], [@CR58]\].

Various clinical trials have been carried out to validate the use of alloDC-based tumor vaccination and results so far have been mixed \[[@CR23], [@CR27], [@CR36], [@CR50], [@CR55]--[@CR57]\]. In these studies patients with metastatic RCC, with melanoma, or with early-stage B-cell chronic lymphocytic leukemia were vaccinated with alloDC, either loaded with tumor lysates or apoptotic bodies, or fused to autologous or allogeneic tumor cells. All studies showed the tolerability and safety of this approach, with some partial clinical responses, accompanied by evidence of tumor-specific T-cell activation. On the whole, alloDC based vaccines appeared less effective than autologous DC used in previous trials. This might be due to a lack in HLA class I matching \[[@CR55], [@CR56]\]. Of note, most favorable results in murine models were obtained with "semi-allogeneic" DC, i.e. alloDC that were partially MHC-matched \[[@CR58]\]. While allo-MHC class II molecules may provide beneficial Th activity, it is likely that for a CTL response to be induced, at least partial MHC class I matching is required. This was recently confirmed by a vaccination study in colorectal cancer patients, showing that tumor lysate-loaded DC with one haplotype miss-match induced stronger anti-tumor immune responses, accompanied by stabilized or reduced CEA serum levels, as compared to fully autologous DC \[[@CR50]\]. Similarly, vaccination with autologous melanoma/alloDC hybrids, which per definition would present TAA peptides in the context of matched (in this case autologous) HLA class I molecules, resulted in clinical responses, long survival times, and high-frequency post-vaccination T cell responses against a broad range of melanoma epitopes \[[@CR55], [@CR57]\]. These studies clearly demonstrate the feasibility of generating TAA-specific T-cell responses in vivo on an allo-background: anti-tumor responses were quite clearly not drowned out by collateral allo-T-cell responses.

The MUTZ-3 cell line: a sustainable source of alloDC for vaccination purposes {#Sec8}
=============================================================================

While CD34-DC may be more powerful vaccine vehicles than the more commonly used MoDC, the use of in vitro generated CD34-DC is complicated by the lenghty and laborious methodologies involved, considerable functional and phenotypic variability between batches (both intra- and inter-individual) and the extremely low frequency of CD34^+^ DC precursor cells in peripheral blood. A human CD34^+^ DC line would be an attractive alternative, allowing the preparation of large quantities of standardized alloDC that would provide an off-the-shelf alternative for autologous DC-based tumor vaccination purposes. Over the past 8 years we have gathered evidence that the cytokine-dependent CD34^+^ human acute myeloid leukemia (AML) cell line MUTZ-3 represents such a sustainable supply of DC \[[@CR34], [@CR39]--[@CR41]\]. By matching for the HLA-A2 and/or -A3 alleles (both present on MUTZ--3), \>50% of patients should be eligible for MUTZ-3-based vaccination regimens.

MUTZ-3 is a heterogeneous AML cell line consisting of CD34+ and CD14+ cell populations \[[@CR25]\]. CD34^+^ MUTZ-3 cells behave as the immortalized equivalents of CD34^+^ DC precursor cells \[[@CR34], [@CR40]\]. Upon stimulation with specific cytokine cocktails, CD34^+^ MUTZ-3 progenitors pass through a CD14^+^ state, lose their proliferative capacity, and acquire a phenotype consistent with either classic IDC or LC with respective characteristic and mutually exclusive expression of DC-SIGN or Langerin and Birbeck Granules \[[@CR40]\]. MUTZ3-DC display the full range of functional MHC- and CD1d-mediated antigen processing and presentation pathways and upon maturation (induced by cocktails comprising IL-6, PGE2, TNF-α, IL-1β, IFN-α, or Poly:IC) up-regulate co-stimulatory molecules, express CD83, and display an enhanced allogeneic T-cell priming ability in mixed leukocyte reactions (MLR) \[[@CR34], [@CR40]\]. By extensive functional characterization of MUTZ3-DC (differentiated to either IDC or LC), we aimed to elucidate their ability to induce a specific T-cell response and to serve as a clinical vehicle of tumor vaccines \[[@CR39], [@CR41]\]. The lymph node (LN) homing potential of MUTZ3-DC was confirmed in a trans-well assay in response to the LN-derived chemokines CCL19 and CCL21 and shown to be comparable to MoDC \[[@CR41]\]. This is in line with their CCR7 expression and suggestive of their in vivo ability to reach the paracortical T-cell areas of LN. We demonstrated that functional (i.e. tumor-recognizing) CTL clones could be generated against multiple tumor-associated epitopes (derived from MART-1, CEA, Her-2/*neu*, and PSA) by stimulating CD8β^+^ CTL precursors with peptide-loaded allogeneic, HLA-A2-matched MUTZ3-DC (both IDC and LC) \[[@CR39], [@CR41]\]. Importantly, a consistent induction capacity, as determined by MHC tetramer (Tm) binding, was found in multiple donors (i.e. across a range of allo-MHC haplotypes) and at an efficiency comparable to autologous peptide-loaded MoDC. TAA-specific CTLs generated by MUTZ3-DC were of low-to-intermediate functional avidity. Retroviral transduction with IL-12p70 significantly improved CTL priming efficiency of both MUTZ-3-derived IDC and LC and resulted in priming of MART-1 specific CTL with higher functional avidity, a more defined memory-effector phenotype, and a higher cytolytic potential for MART-1-expressing melanoma cells \[[@CR41]\].

Planned clinical trials are expected to demonstrate the efficacy of allo-DC cell lines in the in vivo priming of specific effector T-cells in the face of an ongoing competition with simultaneously primed allogeneic T-cells. It will be of particular interest to establish the number of effective booster vaccinations that can be administered following the prime vaccination, before allogeneic responses become too restrictive and alternative vaccine formulations may have to be applied in alternating prime-boost approaches.

The future: from whole-cell vaccines to DC-targeted vaccines? {#Sec9}
=============================================================

While currently explored allogeneic approaches in whole tumor cell and/or DC-based vaccination procedures represent an improvement in terms of standardization and cost effectiveness over their autologous counterparts, they nevertheless entail the culture of large batches of cells under cGMP conditions. It is clear that further optimization of these in vitro culture methodologies is required to improve therapeutic efficacy of DC-based vaccines. In order to home to draining LN and subsequently activate specific T cells, DC have to reach the correct level of activation and display the correct set of chemokine receptors, expression of which should be precisely orchestrated, both spatially and chronologically \[[@CR33]\]. In vitro generated and readministered DC do not necessarily fulfill all these requirements, as only very low numbers of injected DC (typically \<1%) reach the draining lymph nodes \[[@CR7]\]. Therefore, next to improving whole tumor cell and/or DC-based vaccines, direct in vivo approaches certainly deserve more attention. Of note, many novel tools have now become available for targeting DC \[[@CR49]\]. In parallel studies, therefore, we currently pursue the latter approach using DC-targeting adenoviral vectors carrying antigenic payloads \[[@CR5], [@CR6], [@CR54]\]. At the end of the day, results from rigidly controlled and comparative clinical studies should reveal those immunotherapeutic approaches that deserve inclusion into regular cancer patient care.
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